Granted Patent
B2
US 9,796,781 · App. 14/927,349 · Granted Oct 24, 2017
Markers of acute myeloid leukemia stem cells
C07K16/2803C07K16/28C07K16/2896C07K16/30C12N5/0093C12N5/0694C12Q1/6886G01N33/5011G01N33/57426A61K2039/505A61K2039/507C07K2317/24C07K2317/73C07K2317/75C07K2317/76C12Q2600/112C12Q2600/136G01N2500/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
Claims (2)
1. A method for reducing the growth of acute myeloid leukemia (AML) cancer stem cells ex vivo, the method comprising: contacting the AML cancer stem cells ex vivo with an anti-CD47 antibody that blocks the interaction of CD47 with SIRPα; wherein the anti-CD47 antibody reduces the growth of the AML cancer stem cells ex vivo by enhancing phagocytosis of the AML cancer stem cells.
2. The method of claim 1 , wherein the CD47 antibody is an intact antibody molecule.
Assignments (2)
CONFIRMATORY LICENSE
Recorded Aug 16, 2023
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064602/0445 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 10, 2015
From: MAJETI, RAVINDRA; WEISSMAN, IRVING L.
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 037006/0119 →
Continuity (6)
Continuation In Part
PCTUS2009000224
· Jan 13, 2009
Provisional Application
61011324
· Jan 15, 2008